Summary of JAK2 p.V617F testing in patients with MPN
| . | . | JAK2 p.V617F N (% each diagnosis) . | JAK2 p.V617F allele burden* . | ||
|---|---|---|---|---|---|
| N (% total) . | PB . | BM . | PB . | BM . | |
| All patients | 388 | 264 (68) | 264 (68) | 52.7 (3.3-100) | 51.4 (3.1-98.7) |
| PMF | 243 (63) | 156 (64) | 156 (64) | 48.8 (3.8-100) | 47.4 (3.1-98.7) |
| Post-ET MF | 38 (10) | 13 (34) | 13 (34) | 62.6 (24.4-94.5) | 63.8 (21.3-89.7) |
| Post-PV MF | 48 (12) | 48 (100) | 48 (100) | 92.6 (5.2-98.8) | 91.5 (10.5-98.1) |
| Primary ET | 32 (8) | 22 (69) | 22 (69) | 18.3 (3.3-81.6) | 18.9 (4.3-75.7) |
| Primary PV | 27 (7) | 25 (93) | 25 (93) | 60.2 (7.9-92.4) | 60.1 (5.3-98.1) |
| . | . | JAK2 p.V617F N (% each diagnosis) . | JAK2 p.V617F allele burden* . | ||
|---|---|---|---|---|---|
| N (% total) . | PB . | BM . | PB . | BM . | |
| All patients | 388 | 264 (68) | 264 (68) | 52.7 (3.3-100) | 51.4 (3.1-98.7) |
| PMF | 243 (63) | 156 (64) | 156 (64) | 48.8 (3.8-100) | 47.4 (3.1-98.7) |
| Post-ET MF | 38 (10) | 13 (34) | 13 (34) | 62.6 (24.4-94.5) | 63.8 (21.3-89.7) |
| Post-PV MF | 48 (12) | 48 (100) | 48 (100) | 92.6 (5.2-98.8) | 91.5 (10.5-98.1) |
| Primary ET | 32 (8) | 22 (69) | 22 (69) | 18.3 (3.3-81.6) | 18.9 (4.3-75.7) |
| Primary PV | 27 (7) | 25 (93) | 25 (93) | 60.2 (7.9-92.4) | 60.1 (5.3-98.1) |
Median and range are shown.